Department of Surgical Intensive Care Unit, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, 100730, China.
College of Engineering and Computer Science, Australian National University, Canberra, 2600, Australia.
BMC Pulm Med. 2021 May 13;21(1):160. doi: 10.1186/s12890-021-01526-2.
To investigate the indications for high-flow nasal cannula oxygen (HFNC) therapy in patients with hypoxemia during ventilator weaning and to explore the predictors of reintubation when treatment fails.
Adult patients with hypoxemia weaning from mechanical ventilation were identified from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. The patients were assigned to the treatment group or control group according to whether they were receiving HFNC or non-invasive ventilation (NIV) after extubation. The 28-day mortality and 28-day reintubation rates were compared between the two groups after Propensity score matching (PSM). The predictor for reintubation was formulated according to the risk factors with the XGBoost algorithm. The areas under the receiver operating characteristic curve (AUC) was calculated for reintubation prediction according to values at 4 h after extubation, which was compared with the ratio of SpO/FiO to respiratory rate (ROX index).
A total of 524,520 medical records were screened, and 801 patients with moderate or severe hypoxemia when undergoing mechanical ventilation weaning were included (100 < PaO2/FiO2 ≤ 300 mmHg), including 358 patients who received HFNC therapy after extubation in the treatment group. There were 315 patients with severe hypoxemia (100 < PaO2/FiO2 ≤ 200 mmHg) before extubation, and 190 patients remained in the treatment group with median oxygenation index 166[157,180] mmHg after PSM. There were no significant differences in the 28-day reintubation rate or 28-day mortality between the two groups with moderate or severe hypoxemia (all P > 0.05). Then HR/SpO was formulated as a predictor for 48-h reintubation according to the important features predicting weaning failure. According to values at 4 h after extubation, the AUC of HR/SpO was 0.657, which was larger than that of ROX index (0.583). When the HR/SpO reached 1.2 at 4 h after extubation, the specificity for 48-h reintubation prediction was 93%.
The treatment effect of HFNC therapy is not inferior to that of NIV, even on patients with oxygenation index from 160 to 180 mmHg when weaning from ventilator. HR/SpO is more early and accurate in predicting HFNC failure than ROX index.
探讨高流量鼻导管吸氧(HFNC)治疗机械通气撤机过程中低氧血症患者的适应证,并探讨治疗失败时再次插管的预测因素。
从医疗信息集市重症监护 IV 版(MIMIC-IV)数据库中确定机械通气撤机过程中出现低氧血症的成年患者。根据患者拔管后是否接受 HFNC 或无创通气(NIV)治疗,将患者分配到治疗组或对照组。通过倾向性评分匹配(PSM)比较两组患者的 28 天死亡率和 28 天再插管率。根据 XGBoost 算法的风险因素制定再插管预测因素。根据拔管后 4 小时的数值计算再插管预测的受试者工作特征曲线下面积(AUC),并与 SpO/FiO 与呼吸频率的比值(ROX 指数)进行比较。
共筛选出 524520 份病历,纳入 801 例机械通气撤机过程中出现中重度低氧血症(100<PaO2/FiO2≤300mmHg)的患者,其中 358 例患者在治疗组中接受了拔管后的 HFNC 治疗。有 315 例患者在拔管前存在严重低氧血症(100<PaO2/FiO2≤200mmHg),190 例患者在 PSM 后仍留在治疗组,中位氧合指数为 166[157,180]mmHg。中重度低氧血症患者的 28 天再插管率或 28 天死亡率在两组之间无显著差异(均 P>0.05)。然后根据预测撤机失败的重要特征,将 HR/SpO 制定为 48 小时再插管的预测因素。根据拔管后 4 小时的值,HR/SpO 的 AUC 为 0.657,大于 ROX 指数(0.583)。当 HR/SpO 在拔管后 4 小时达到 1.2 时,对 48 小时再插管预测的特异性为 93%。
HFNC 治疗的效果不逊于 NIV,甚至对氧合指数在 160-180mmHg 之间的患者也是如此。与 ROX 指数相比,HR/SpO 更早、更准确地预测 HFNC 治疗失败。